The following account is for satirical purposes only, and any individuals or organizations named within it – even those based on real people – are entirely fictional.
A major shakeup in the non-existent psychedelic industry has led to the surprise appointment of former Lykos Therapeutics board member Rick Doblin as the new Executive Director at psychedelic tabloid publisher Psymposia.
“Accusations of ethical oversights levied against both organizations have enabled a clean slate where we can all just be friends again” said a spokesperson for Doblin, who was unavailable for comment due to an extended decompression commitment after attending much of the recent Dead & Company residency at The Sphere in Vegas.
The recent decision by the FDA to reject the Lykos Therapeutics New Drug Application for MDMA-Assisted Therapy as a treatment for PTSD has sent shockwaves through the psychedelic community, with many left grappling for answers that they should probably know are readily contained within them and accessible via non-clinical use of entheogens and vision inducing novel molecules.
The rift between Psymposia and Doblin et al extends back to a time before this whole PsyOp started, back to when both organizations actively collaborated in pursuit of an equitable, ethical, and accessible future of psychedelic therapy. That pipe dream has vanished into a cloud of dust and DMT on the playa, where much of the philanthropic funding for psychedelic research was ultimately directed.
“This new appointment brings with it a world of possibilities; while we can’t be certain of the outcomes, we can rest assured there will be more unhinged vitriol and finger-pointing on social media” commented a spokesperson for Psymposia.
